WO2006126846A1 - Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts - Google Patents
Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts Download PDFInfo
- Publication number
- WO2006126846A1 WO2006126846A1 PCT/KR2006/001993 KR2006001993W WO2006126846A1 WO 2006126846 A1 WO2006126846 A1 WO 2006126846A1 KR 2006001993 W KR2006001993 W KR 2006001993W WO 2006126846 A1 WO2006126846 A1 WO 2006126846A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chemical formula
- aminosalicylic acid
- acid derivative
- represented
- tetrafluorobenzyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 150000003839 salts Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims description 17
- 150000001875 compounds Chemical class 0.000 title description 32
- 239000000126 substance Substances 0.000 claims description 52
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 229960004963 mesalazine Drugs 0.000 claims description 18
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 15
- 229910052700 potassium Inorganic materials 0.000 claims description 15
- 239000011591 potassium Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
- 229910052708 sodium Inorganic materials 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- 238000006243 chemical reaction Methods 0.000 claims description 12
- UPJHEKIKCNDMEX-UHFFFAOYSA-N 2,3,4,5-tetrafluorobenzaldehyde Chemical compound FC1=CC(C=O)=C(F)C(F)=C1F UPJHEKIKCNDMEX-UHFFFAOYSA-N 0.000 claims description 11
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052744 lithium Inorganic materials 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 239000002808 molecular sieve Substances 0.000 claims description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 3
- JRUKCFQBEJZBGU-UHFFFAOYSA-M sodium;2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoate Chemical compound [Na+].C1=C(C([O-])=O)C(O)=CC=C1NCC1=C(F)C(F)=C(C(F)(F)F)C(F)=C1F JRUKCFQBEJZBGU-UHFFFAOYSA-M 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- DQAXFEMDAQCNSI-UHFFFAOYSA-M lithium;2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoate Chemical compound [Li+].C1=C(C([O-])=O)C(O)=CC=C1NCC1=C(F)C(F)=C(C(F)(F)F)C(F)=C1F DQAXFEMDAQCNSI-UHFFFAOYSA-M 0.000 claims 2
- KLOANMLPWLPVSW-UHFFFAOYSA-M potassium;2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoate Chemical compound [K+].C1=C(C([O-])=O)C(O)=CC=C1NCC1=C(F)C(F)=C(C(F)(F)F)C(F)=C1F KLOANMLPWLPVSW-UHFFFAOYSA-M 0.000 claims 2
- 125000000879 imine group Chemical group 0.000 claims 1
- -1 salt compounds Chemical class 0.000 abstract description 12
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- HABROHXUHNHQMY-UHFFFAOYSA-N 2-hydroxy-5-[[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl]methylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C(=C(F)C(=C(F)C=2F)C(F)(F)F)F)=C1 HABROHXUHNHQMY-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000539 dimer Substances 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 159000000000 sodium salts Chemical group 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 229910003002 lithium salt Inorganic materials 0.000 description 4
- 159000000002 lithium salts Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- YIRYOMXPMOLQSO-UHFFFAOYSA-N 2,3,5,6-tetrafluorobenzaldehyde Chemical compound FC1=CC(F)=C(F)C(C=O)=C1F YIRYOMXPMOLQSO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AGWVQASYTKCTCC-UHFFFAOYSA-N (2,3,5,6-tetrafluorophenyl)methanol Chemical compound OCC1=C(F)C(F)=CC(F)=C1F AGWVQASYTKCTCC-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 0 CC*C(*)(c(c(F)c(c(C=O)c1*)F)c1F)I Chemical compound CC*C(*)(c(c(F)c(c(C=O)c1*)F)c1F)I 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Chemical group NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical class [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
Definitions
- This invention relates to a process for preparing tetrafluorobenzyl-5-aminosalicylic acid derivatives represented by the following Chemical Formula I and its pharmaceutically acceptable salt compounds which are useful for the prevention and treatment of acute and chronic neurodegenerative diseases.
- M + represents lithium, sodium or potassium; and R R and R may, independently of one another, be hydrogen or halogen.
- tetrafluorobenzyl derivatives are therapeutically effective in the prevention and treatment of acute and chronic neurodegenerative diseases and can effectively be used to prevent and treat chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; seizure-inducing brain disease such as epilepsy; and ischemic brain disease such as stroke.
- R , R and R are hydrogen or halogen, respectively;
- R is hydroxy, alkyl, alkoxy, halogen, alkoxy substituted with halogen, alkanoyloxy or nitro, and
- R is carboxylic acid or ester of carboxylic acid substituted with C1-C4 alkyl, car- boxyamide, sulfonic acid, halogen or nitro.
- Reaction scheme II shows the process for preparing tetrafluorobenzyl- 5-aminosalicylic acid derivatives.
- a nitrobenzene compound is hydrogenated, and the resulting aniline compound is reacted with tetrafluorobenzyl bromide compound in the presence of triethylamine and dimethylformimide resulting in the production of the desired tetrafluorobenzyl-5-aminosalicylic acid derivative.
- R R and R may, independently of one another, be hydrogen or halogen.
- R R and R may, independently of one another, be hydrogen or halogen.
- An object of this invention is to provide a novel method for producing tetraflu- orobenzyl-5-aminosalicylic acid derivatives while preventing the formation of impurities such as the dimer represented by Chemical Formula in.
- Another object of this invention is to provide a novel method for producing tetrafluorobenzyl- 5 -aminosalicylic acid derivatives by using a tetrafluo- robenzilidine-5-aminosalicylic acid derivative represented by Chemical Formula II as an intermediate.
- another object of this invention is to provide the salt compounds of tetraflu- orobenzyl-5-aminosalicylic acid derivatives which have increased stability and less toxicity.
- reaction scheme I The novel method for producing tetrafluorobenzyl-5-aminosalicylic acid is shown in reaction scheme I.
- the preparation is comprised of the following steps: [37] a) oxidation of tetrafluorobenzyl alcohol, represented by Chemical Formula 1 to tetrafluorobenzaldehyde represented by Chemical Formula 2; [38] b) conversion of tetrafluorobenzaldehyde to tetrafluorobenzilidine- 5 -aminosalicylic acid derivative represented by Chemical Formula II via dehydration-condensation reaction between tetrafluorobenzaldehyde and 5-amino-salicylic acid represented by Chemical Formula 3, and
- M + represents lithium, sodium or potassium; and R R and R may, independently of one another, be hydrogen or halogen.
- M + represents lithium, sodium or potassium; and R R and R may, independently of one another, be hydrogen or halogen.
- Step I Tetrafluorobenzaldehyde is formed via oxidation of tetrafluorobenzyl alcohol
- Step II Tetrafluorobenzaldehyde, as obtained in step I, and 5-amino-salicylic acid undergo a dehydration-condensation reaction in the presence of methylene chloride solvent at room temperature using molecular sieves to form tetrafluo- robenzilidine-5-aminosalicylic acid derivative, represented by Chemical Formula ⁇ , as an imine compound; and
- Step HI The tetrafluorobenzilidine-S-aminosalicylic acid derivative obtained in step ⁇ and represented by Chemical Formula II is hydrogenated using a platinum catalyst and alcohol solvent to produce tetrafluorobenzyl-5-aminosalicylic acid compounds, represented by Chemical Formula I, via contact reduction.
- Tetrafluorobenzaldehyde in step I may be easily prepared via general oxidation of tetrafluorobenzyl alcohol using pyridinium chlorochromate and methylene chloride.
- step ⁇ tetrafluorobenzaldehyde, as obtained in step I, and 5-amino-salicylic acid undergo a dehydration-condensation reaction at room temperature to form tetrafluo- robenzilidine-5-aminosalicylic acid derivative, represented by Chemical Formula ⁇ , according to the procedures reported in J. Org. Chem., 66(6), 2001, 1992-1998.
- step II of this invention is characterized by avoiding a dimer generated in the process of preparing tetrafluorobenzyl-5-aminosalicylic acid compound of the Chemical Formula I, which is reported by the Korean Patent Unexamined Publication No. 2003-0097706.
- step HI a tetrafluorobenzilidine- 5 -aminosalicylic acid derivative represented by
- Chemical Formula ⁇ is hydrogenated using a palladium catalyst and alcohol solvent to produce a tetrafluorobenzyl-5-aminosalicylic acid compound, represented by Chemical Formula I, via contact reduction.
- the reduction reaction of the imine compound in step in of this invention can be performed to give the desired compound, represented by Chemical Formula I, via other general and common reduction procedures using sodium borohydride and alcohol; or a transition metal catalyst and weak acid such as acetic acid.
- This invention provides a novel method for producing tetrafluorobenzyl-
- 5-aminosalicylic acid derivative to prevent the formation of impurities such as the dimer represented by Chemical Formula in.
- this invention is characterized by using a tetrafluo- robenzilidine-5-aminosalicylic acid derivative (Chemical Formula H) as an intermediate in order to prevent the formation of a dimer.
- a further aspect of this invention provides the pharmaceutically acceptable salts of tetrafluorobenzyl-5-aminosalicylic acid, represented by Chemical Formula I.
- the pharmaceutically acceptable salts of the desired compound in this invention include alkali metals such as sodium, potassium and lithium.
- the salts of the desired compound represented by Chemical Formula I of this invention can be prepared by direct crystallization or by lyophilization using an inorganic reagent such as lithium hydroxide, sodium hydroxide or potassium hydroxide in the presence of alcohol, acetone, acetonitrile and other organic solvents.
- an inorganic reagent such as lithium hydroxide, sodium hydroxide or potassium hydroxide in the presence of alcohol, acetone, acetonitrile and other organic solvents.
- the inventors have screened various kinds of the pharmaceutically acceptable salts of the desired compound represented by Chemical Formula I such as alkali metals; alkaline earth metals such as calcium; pharmaceutically acceptable nontoxic salts such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, maleic acid, acetic acid, or citric acid; and organic salts such as N,N-dibenzylethylene diamine or ethylene diamine.
- pharmaceutically acceptable salts of the desired compound represented by Chemical Formula I such as alkali metals; alkaline earth metals such as calcium; pharmaceutically acceptable nontoxic salts such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, maleic acid, acetic acid, or citric acid; and organic salts such as N,N-dibenzylethylene diamine or ethylene diamine.
- this invention provides the salts of sodium, potassium and lithium to have better solubility and stability among the pharmaceutically acceptable salts of the desired compound represented by the chemical formula I.
- this invention provides a novel method for producing tetraflu- orobenzyl-5-aminosalicylic acid derivative; a method which prevents the formation of impurities such as the dimer represented by Chemical Formula m.
- This invention provides a novel method for producing tetrafluorobenzyl-
- 5-aminosalicylic acid derivative by using tetrafluorobenzilidine-5-aminosalicylic acid derivative, represented by Chemical Formula ⁇ , as an intermediate.
- Another object of this invention is to provide the salt compounds of tetraflu- orobenzyl-5-aminosalicylic acid derivative with better stability of the desired compound and with less toxicity.
- Figure 1 shows the protective effects of the tetrafluorobenzyl-5-aminosalicylic acid compound, as well as the protective effects of the potassium and sodium salt forms of tetrafluorobenzyl-5-aminosalicylic acid in rats with focal cerebral ischemia by occlusion of the middle cerebral artery.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007014797A MX2007014797A (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts. |
CN2006800179208A CN101180263B (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
CA2608553A CA2608553C (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
US11/915,180 US7495126B2 (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
EP06768635.2A EP1883619B8 (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
BRPI0611484-9A BRPI0611484A2 (en) | 2005-05-25 | 2006-05-25 | process for preparing substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
JP2008513376A JP5006311B2 (en) | 2005-05-25 | 2006-05-25 | Substituted tetrafluorobenzylaniline compound and method for producing pharmaceutically acceptable salt thereof |
AU2006250207A AU2006250207B2 (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2005-0044298 | 2005-05-25 | ||
KR20050044298 | 2005-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006126846A1 true WO2006126846A1 (en) | 2006-11-30 |
Family
ID=37452224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/001993 WO2006126846A1 (en) | 2005-05-25 | 2006-05-25 | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts |
Country Status (11)
Country | Link |
---|---|
US (1) | US7495126B2 (en) |
EP (1) | EP1883619B8 (en) |
JP (1) | JP5006311B2 (en) |
KR (1) | KR20060121768A (en) |
CN (1) | CN101180263B (en) |
AU (1) | AU2006250207B2 (en) |
BR (1) | BRPI0611484A2 (en) |
CA (1) | CA2608553C (en) |
MX (1) | MX2007014797A (en) |
RU (1) | RU2413715C2 (en) |
WO (1) | WO2006126846A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009064084A3 (en) * | 2007-11-12 | 2009-07-16 | Neurotech Co Ltd | Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts |
CN106831462A (en) * | 2016-12-30 | 2017-06-13 | 浙江普洛家园药业有限公司 | Potassium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate impurity B and its preparation method and application |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102617383A (en) * | 2012-03-20 | 2012-08-01 | 横店集团家园化工有限公司 | Salfaprodil crystal forms, preparation methods, and sterile powder containing salfaprodil crystals |
CN104042598B (en) * | 2013-03-15 | 2018-01-16 | 江苏先声药业有限公司 | A kind of pharmaceutical composition and its application in treatment scald medicament is prepared |
WO2017215591A1 (en) * | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Use of lithium benzoate for treating central nervous system disorders |
TWI626043B (en) * | 2017-06-13 | 2018-06-11 | 心悅生醫股份有限公司 | Use of Lithium Benzoate for Treating Central Nervous System Disorders |
CN108164431B (en) * | 2018-01-12 | 2021-10-08 | 浙江普洛家园药业有限公司 | 2-hydroxy-5- (2,3,5, 6-tetrafluoro-4-trifluoromethyl benzylamino) benzoic acid and preparation method thereof |
CN113995723A (en) * | 2020-07-27 | 2022-02-01 | 浙江普洛家园药业有限公司 | Preparation method of Sofadil freeze-dried powder injection, product and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527814A (en) * | 1992-03-06 | 1996-06-18 | Rhone Poulenc Rorer S.A. | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis |
WO1999001421A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
JP2000212141A (en) * | 1999-01-13 | 2000-08-02 | Warner Lambert Co | Diarylamine |
JP2000273041A (en) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | Inhibitor of neurocyte apoptosis with glutamic acid cytotoxicity |
KR20030097706A (en) | 2002-06-19 | 2003-12-31 | 주식회사 뉴로테크 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
KR20040066639A (en) | 2003-01-20 | 2004-07-27 | 주식회사 뉴로테크 | Method for inhibition of necrosis induced by neurotrophin |
-
2006
- 2006-05-25 MX MX2007014797A patent/MX2007014797A/en active IP Right Grant
- 2006-05-25 JP JP2008513376A patent/JP5006311B2/en not_active Expired - Fee Related
- 2006-05-25 BR BRPI0611484-9A patent/BRPI0611484A2/en not_active IP Right Cessation
- 2006-05-25 CN CN2006800179208A patent/CN101180263B/en not_active Expired - Fee Related
- 2006-05-25 EP EP06768635.2A patent/EP1883619B8/en not_active Not-in-force
- 2006-05-25 WO PCT/KR2006/001993 patent/WO2006126846A1/en active Application Filing
- 2006-05-25 CA CA2608553A patent/CA2608553C/en not_active Expired - Fee Related
- 2006-05-25 AU AU2006250207A patent/AU2006250207B2/en not_active Ceased
- 2006-05-25 RU RU2007148018/04A patent/RU2413715C2/en not_active IP Right Cessation
- 2006-05-25 KR KR1020060047284A patent/KR20060121768A/en active IP Right Grant
- 2006-05-25 US US11/915,180 patent/US7495126B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527814A (en) * | 1992-03-06 | 1996-06-18 | Rhone Poulenc Rorer S.A. | Use of 2-amino-6-(trifluoromethoxy)benzothiazole for obtaining a medicament for the treatment of amyotrophic lateral sclerosis |
WO1999001421A1 (en) * | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
JP2000212141A (en) * | 1999-01-13 | 2000-08-02 | Warner Lambert Co | Diarylamine |
JP2000273041A (en) * | 1999-01-19 | 2000-10-03 | Sankyo Co Ltd | Inhibitor of neurocyte apoptosis with glutamic acid cytotoxicity |
KR20030097706A (en) | 2002-06-19 | 2003-12-31 | 주식회사 뉴로테크 | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
WO2004000786A1 (en) | 2002-06-19 | 2003-12-31 | Neurotech Co., Ltd. | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
KR20040066639A (en) | 2003-01-20 | 2004-07-27 | 주식회사 뉴로테크 | Method for inhibition of necrosis induced by neurotrophin |
Non-Patent Citations (1)
Title |
---|
See also references of EP1883619A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009064084A3 (en) * | 2007-11-12 | 2009-07-16 | Neurotech Co Ltd | Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts |
AU2008321691B2 (en) * | 2007-11-12 | 2013-05-23 | Neurotech Pharmaceuticals Co., Ltd | Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts |
CN106831462A (en) * | 2016-12-30 | 2017-06-13 | 浙江普洛家园药业有限公司 | Potassium 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)benzoate impurity B and its preparation method and application |
Also Published As
Publication number | Publication date |
---|---|
EP1883619A4 (en) | 2010-05-12 |
JP2008546642A (en) | 2008-12-25 |
CA2608553C (en) | 2012-04-24 |
KR20060121768A (en) | 2006-11-29 |
EP1883619B1 (en) | 2013-03-20 |
RU2413715C2 (en) | 2011-03-10 |
CA2608553A1 (en) | 2006-11-30 |
JP5006311B2 (en) | 2012-08-22 |
US20080167492A1 (en) | 2008-07-10 |
CN101180263A (en) | 2008-05-14 |
AU2006250207A1 (en) | 2006-11-30 |
US7495126B2 (en) | 2009-02-24 |
EP1883619B8 (en) | 2013-05-01 |
RU2007148018A (en) | 2009-06-27 |
CN101180263B (en) | 2011-11-02 |
BRPI0611484A2 (en) | 2010-09-08 |
MX2007014797A (en) | 2008-02-15 |
AU2006250207B2 (en) | 2011-09-01 |
EP1883619A1 (en) | 2008-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006250207B2 (en) | Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts | |
EP2213651B1 (en) | Resolution of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane | |
US5354760A (en) | Crystalline Tiagabine monohydrate, its preparation and use | |
WO2019242192A1 (en) | Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam | |
EP3100735B1 (en) | Crystalline fosaprepitant dicyclohexylamine salt and its preparation | |
KR840001836B1 (en) | Process for the preparation of 9-aminoalkyl fluorenes | |
Fodor et al. | Use of acyl migration in separating diastereoisomeric amino alcohols | |
CN105348262A (en) | Improved method for preparing Dabigatran etexilate | |
CN101270074A (en) | Method for preparing high purity mitiglinide calcium | |
KR100913684B1 (en) | Novel crystallization of the trometamol salt of R-thioctic acid, method for producing the same and medicament comprising the same | |
JP2816431B2 (en) | 5-Substituted ornithine derivatives | |
HU229188B1 (en) | Process for the preparation of n-[(s)-1-carboxybutyl]-(s)-alanine esters and their use for synthesizing perindopril | |
CH619935A5 (en) | ||
CN110642781B (en) | Synthetic method of 3-fluoro-4-methylpyridine-2-carboxylic acid | |
CA1076117A (en) | Process for the production of new arylic ethers and their derivatives | |
JPS5892646A (en) | Benzylidene derivative | |
CA1063619A (en) | Process for the preparation of new benzylamino-acanoic acids ands compounds thereof | |
FR3067711A1 (en) | INHIBITORS OF CATECHOL-O-METHYL-TRANSFERASE (COMT) | |
EP1721889A1 (en) | Process for the preparation of phenethylamine derivatives | |
NZ262219A (en) | 3-hydroxyanthranilic acid derivatives, preparation, intermediates and pharmaceutical compositions thereof | |
KR100751888B1 (en) | Process of pharmaceutically acceptable salts of 5-(substituted phenylalkyl)amino salicylic acid and 5-(substituted phenylpropyl)amino salicylic acid | |
CA1078869A (en) | Process for the preparation of novel benzylamines | |
CN109180511A (en) | A kind of preparation method of tetracaine hydrochloride | |
KR20100079285A (en) | A method for preparing crotonic acid derivatives | |
JPS6256860B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680017920.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008513376 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2608553 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006768635 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11915180 Country of ref document: US Ref document number: 2006250207 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/014797 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5345/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2006250207 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2007148018 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006768635 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0611484 Country of ref document: BR Kind code of ref document: A2 |